Tiago Outeiro, PhD, University Medical Center Gottingen, Gottingen, Germany, presents exciting recent breakthroughs in the field of Parkinson's disease. With technological advancements in neuroimaging and biomarkers, the definition of Parkinson's disease has become more precise. Notably, a newly validated assay known as the seed amplification assay (SAA) can detect the presence of aggregated synuclein in an individual's cerebrospinal fluid (CSF). This information, in combination with clinical criteria and imaging, allows the differentiation of patient groups and may guide tailored approaches in prodromal or early Parkinson's disease. This interview took place at the European Academy of Neurology (EAN) 2023 Congress in Budapest, Hungary.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть